title: Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
abstract: This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone.
  
  
  
  Charts from 26 consecutive patients able to obtain commercial vorinostat were analyzed for response and safety data.
  
  
  
  The overall response rate was 31%, and the clinical beneficial rate was 50%. The median duration of response was 3 months, and the median overall survival was 28.5 months. The most common grade 3 and 4 toxicities were hematologic and metabolic, including neutropenia (44%), thrombocytopenia (53%), and transaminase elevations (aspartate aminotransferase 9% and alanine aminotransferase 6%). No thromboembolic events or febrile neutropenia were observed.
  
  
  
  These observations demonstrate that the addition of vorinostat to patients with lenalidomide- and dexamethasone-refractory multiple myeloma was associated with moderate response and was well-tolerated, warranting further assessment in a larger prospective study.
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Elizabeth
authors: E
authors: Bilotti
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: David H
authors: DH
authors: Vesole
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Laura
authors: L
authors: McBride
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Linda
authors: L
authors: Schmidt
authors: Department of Hematology/Oncology, Columbia University Medical Center, New York, NY.
authors: Zhijie
authors: Z
authors: Gao
authors: Department of Hematology/Oncology, Jefferson University Hospital, Philadelphia, PA.
authors: Madiha
authors: M
authors: Gilani
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Ann
authors: A
authors: McNeill
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Urszula
authors: U
authors: Bednarz
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Joshua
authors: J
authors: Richter
authors: John Theurer Cancer Center, Hackensack, NJ.
authors: Anthony
authors: A
authors: Mato
authors: Pharmacyclics, Inc, Sunnyvale, CA.
authors: Thorsten
authors: T
authors: Graef
authors: John Theurer Cancer Center, Hackensack, NJ. Electronic address: davids.siegel@hackensackmeridian.org.
authors: David S
authors: DS
authors: Siegel
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D012008:Recurrence; D019233:Retreatment; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome; D000077337:Vorinostat
chemical_list: D006877:Hydroxamic Acids; D013792:Thalidomide; D000077337:Vorinostat; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: Histone deacetylase inhibitor; IMiD; Refractory relapse; Relapsed/refractory